

BEST of ESMO BREAST CANCER UAE

SUNDAY 15TH JUNE, 2025

An ESMO Licensed Event



Hosted By



AGENDA

UAE Time	
8:00 - 8:30	Registration
8:30 - 8:35	Welcome & Introduction
Session 1: Advances in Breast Cancer Treatment and Trials	
Moderated by : Dr. Aydah Al Awadhi	
8:35 - 8:47	Dr. Maroun El Khoury 300MO - Puxitatum samrotecan (P-Sam, AZD8205) in patients (pts) with HR+/HER2- breast cancer (BC): A first-in-human phase I/IIa dose escalation and expansion study
8:47 - 8:59	Dr. Patrizia Porcu 152MO - Post-mastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: Analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]
8:59 - 9:11	Dr. Ibrahim Abu-Gheida 153MO - HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): A non-inferiority, open-label, phase III randomized trial
9:11 - 9:23	Dr. Rita A. Sakr 267MO - A deep learning model for breast shear wave elastography to improve breast cancer diagnosis (INSPIRED 006): An international, multicenter analysis
9:23 - 9:35	Dr. Hassan Ghazal LBA2 - Rates of pathologic complete response after VV1 and cemiplimab (alone and in treatment sequence-strategy) in the neoadjuvant setting: Results from the I-SPY 2.2 trial)
9:35 - 9:55	Speaker: Dr. Dalia Elshorbagy Breaking New Grounds the Management of HR+ HER2- eBC
9:55 - 10:10	Coffee Break
10:10 - 10:40	ASCO 2025 Early BREAST CANCER UPDATES Speaker: Dr. Aydah Al Awadhi Panelists: Prof. Humaid Al Shamsi, Prof. Giuseppe Curigliano Prof. Valentina Guarneri, Dr. Hassan Ghazal
10:40 - 11:10	ASCO 2025 Metastatic BREAST CANCER UPDATES Speaker: Dr. Saeed Rafii Panelists: Prof. Giuseppe Curigliano, Dr. Gregory Vidal, Dr. Anwar Al Nouri Dr. Maha Al Sindi, Dr. Meteb El-Foheidi



AGENDA

Session 2: Precision Therapy and Fertility in Breast Cancer Care

Moderated by : Dr. Meteb El-Foheidi

11:10 - 11:22	Prof. Nagi El-Saghir 297O - Imlunestrant (Imlu) with or without abemaciclib (Abema) in advanced breast cancer (ABC): A subgroup analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients (pts) from EMBER-3
11:22 - 11:34	Dr. Emad Dawoud 415O - Predictive factors of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in the POSITIVE trial
11:34 - 11:46	Dr. Husam Marashi 416O - Safety of having a subsequent pregnancy after a prior diagnosis of breast cancer during pregnancy (PrBC) in young BRCA carriers
11:46 - 11:58	Dr. Maha Al Sindi 298MO - Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC
11:58 - 12:10	Dr. Gregory Vidal 299MO - DESTINY-Breast06 (DB-06) post-hoc analysis by physician's choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor-positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)
12:10 - 12:50	Moderated by: Dr. Dina Hamza Speaker: Prof. Valentina Guarneri Abemaciclib Across the Spectrum: From Early-Stage to Advanced Breast Cancer
12:50 - 13:20	Moderated by: Prof. Humaid Al Shamsi Speaker: Prof. Giuseppe Curigliano pVerify trial and real world data in management of HR+ HER2- mBC Speaker: Dr. Aydah Al Awadhi Management of HER2 + mBC
13:20 - 14:30	Lunch Break



AGENDA

Session 3: Neoadjuvant and Adjuvant Advances in Breast Cancer

Moderated by : Prof. Humaid Al Shamsi, Dr. Falah Al Khatib, Dr. Sonia Otsmane

14:30 - 14:42	Dr. Syed Hammad Tirmazy 20 - Integrating tumor infiltrating lymphocytes and nodal status for risk stratification in patients (pts) with triple-negative breast cancer (TNBC) and pathological complete response (pCR) after neoadjuvant treatment (NAT)
14:42 - 14:54	Dr. Dina Hamza 1890 - Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/ HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial
14:54 - 15:06	Dr. Amin Abyad 192MO - Primary endpoint of ROSALINE: A phase II neoadjuvant study of endocrine therapy (ET) and entrectinib in invasive lobular breast carcinoma (ILBC)
15:06 - 15:18	Dr. Aref Chehal 3MO - Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial
15:18 - 15:30	Dr. Nouri Bennini 303MO - Zanidatamab (Zani) + chemotherapy (Chemo) for patients (Pts) with HER2- expressing metastatic breast cancer (mBC): Final results of a phase I trial
15:30 - 15:40	Coffee Break



AGENDA

Session 4: Molecular and Imaging Insights in Breast Cancer Trials

Moderated by : Dr. Diaeddine Trad, Dr. Fathi Azribi

15:40 - 15:56	Dr. Dima Abdul Jabbar 304MO - Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)
15:56 - 16:08	Dr. Almutadha Mula Kh 305MO - Phase II trial of TDM-1 and palbociclib in metastatic HER2 positive breast cancer
16:08 - 16:20	Dr. Hassan Shahryar 6MO - Baseline ctDNA and methylation status as predictors of treatment benefit in the phase III post MONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients
16:20 - 16:30	Dr. Hala Abdellatif 193MO - Predictive value of FDG-PET/CT and MRI for neoadjuvant immunotherapy (IO) response in early-stage triple-negative breast cancer (eTNBC): Exploratory analysis of the phase II BELLINI trial
16:30 - 16:40	Closing Remarks